Pharsight

Glaxosmithkline patents expiration

1. Advil Allergy Sinus patents expiration

ADVIL ALLERGY SINUS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287 GLAXOSMITHKLINE Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
Feb, 2027

(3 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ADVIL ALLERGY SINUS family patents

Family Patents

2. Advil Pm patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883849 GLAXOSMITHKLINE Treatment of sleep disturbances
Jan, 2022

(1 year, 8 months ago)

US9155718 GLAXOSMITHKLINE Treatment of sleep disturbances
Jan, 2022

(1 year, 8 months ago)

Drugs and Companies using DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN ingredient

Market Authorisation Date: 21 December, 2005

Treatment: A method of treating a patient suffering from a pain associated sleep disturbance comprising administering a liquid composition formulated inside a soft gel capsule, as claimed, to the patient

Dosage: CAPSULE;ORAL

How can I launch a generic of ADVIL PM before it's drug patent expiration?
More Information on Dosage

ADVIL PM family patents

Family Patents

3. Advil Pm patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263647 GLAXOSMITHKLINE Treatment of sleep disturbances
May, 2022

(1 year, 3 months ago)

Drugs and Companies using DIPHENHYDRAMINE CITRATE; IBUPROFEN ingredient

Market Authorisation Date: 21 December, 2005

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ADVIL PM before it's drug patent expiration?
More Information on Dosage

ADVIL PM family patents

Family Patents

4. Anoro Ellipta patents expiration

ANORO ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(6 months ago)

US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 6 months from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(1 year, 7 months from now)

US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776895 GLAXOSMITHKLINE Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Sep, 2022

(1 year, 17 days ago)

US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 6 months from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(1 year, 9 months from now)

US8511304 GLAXOSMITHKLINE Medicament dispenser
Jun, 2027

(3 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(4 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Mai...

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

5. Arnuity Ellipta patents expiration

ARNUITY ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(4 years from now)

US9333310

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2028

(4 years from now)

US8113199

(Pediatric)

GLAXOSMITHKLINE Counter for use with a medicament dispenser
Apr, 2028

(4 years from now)

US8161968

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Aug, 2028

(4 years from now)

US8201556 GLAXOSMITHKLINE Medicament dispenser
Feb, 2029

(5 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(6 years from now)

US8534281

(Pediatric)

GLAXOSMITHKLINE Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

US8746242

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Mar 1, 2026

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 20 August, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

Family Patents

6. Children's Advil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(7 months from now)

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 27 June, 1996

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

CHILDREN'S ADVIL family patents

Family Patents

7. Children's Advil Allergy Sinus patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(7 months from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 February, 2004

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

CHILDREN'S ADVIL ALLERGY SINUS family patents

Family Patents

8. Jesduvroq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11643397 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2023

(3 months ago)

US8324208 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Dec, 2028

(5 years from now)

US11117871 GLAXOSMITHKLINE Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Mar, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815884 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(3 years from now)

US8557834 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(3 years from now)

US11649217 GLAXOSMITHKLINE Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Mar, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 1, 2028

Drugs and Companies using DAPRODUSTAT ingredient

NCE-1 date: 2027-02-01

Market Authorisation Date: 01 February, 2023

Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia

Dosage: TABLET;ORAL

More Information on Dosage

JESDUVROQ family patents

Family Patents

9. Nicorette patents expiration

NICORETTE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323683 GLAXOSMITHKLINE Flavoring of drug-containing chewing gums
Apr, 2028

(4 years from now)

US8940772 GLAXOSMITHKLINE Nicotine lozenge composition
Apr, 2029

(5 years from now)

US8501164 GLAXOSMITHKLINE Nicotine lozenge compositions
Jun, 2029

(5 years from now)

Drugs and Companies using NICOTINE POLACRILEX ingredient

Market Authorisation Date: 09 February, 1996

Treatment: NA

Dosage: GUM, CHEWING;BUCCAL

How can I launch a generic of NICORETTE before it's drug patent expiration?
More Information on Dosage

NICORETTE family patents

Family Patents

10. Trelegy Ellipta patents expiration

TRELEGY ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(6 months ago)

US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 6 months from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(1 year, 7 months from now)

US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776895 GLAXOSMITHKLINE Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Sep, 2022

(1 year, 17 days ago)

US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 6 months from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(1 year, 9 months from now)

US8511304 GLAXOSMITHKLINE Medicament dispenser
Jun, 2027

(3 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(4 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Sep 9, 2023
New Strength (NS) Sep 9, 2023

Drugs and Companies using FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via top...

Dosage: POWDER;INHALATION

More Information on Dosage

TRELEGY ELLIPTA family patents

Family Patents

11. Ventolin Hfa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7832351 GLAXOSMITHKLINE Actuation indicator for a dispensing device
Jun, 2023

(3 months ago)

US7832351

(Pediatric)

GLAXOSMITHKLINE Actuation indicator for a dispensing device
Dec, 2023

(2 months from now)

US7500444 GLAXOSMITHKLINE Actuation indicator for a dispensing device
Feb, 2026

(2 years from now)

US7500444

(Pediatric)

GLAXOSMITHKLINE Actuation indicator for a dispensing device
Aug, 2026

(2 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 19 April, 2001

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

VENTOLIN HFA family patents

Family Patents

12. Zejula patents expiration

ZEJULA's oppositions filed in EPO
ZEJULA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436185 GLAXOSMITHKLINE Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Apr, 2029

(5 years from now)

US8071623 GLAXOSMITHKLINE Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071579 GLAXOSMITHKLINE DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(3 years from now)

US8143241 GLAXOSMITHKLINE DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(3 years from now)

US8859562 GLAXOSMITHKLINE Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(7 years from now)

US11673877 GLAXOSMITHKLINE Niraparib compositions
Mar, 2038

(14 years from now)

US11091459 GLAXOSMITHKLINE Niraparib compositions
Mar, 2038

(14 years from now)

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 26 April, 2023

Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status; A method of treatment of recurrent ov...

Dosage: TABLET;ORAL

More Information on Dosage

ZEJULA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic